Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Avalo Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +6 vs. Q4 2023
- Shares held
- 87.5K
- +64.5K (+281.0%) vs. Q4 2023
- Total value
- $1.90M
- +$1.69M (+806.5%) vs. Q4 2023
- New holders
- 8
- 3 more added
- Sold out
- 2
- 4 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 126 | $1.31B |
| Q1 2026 | 97 | $469.6M |
| Q4 2025 | 84 | $361.1M |
| Q3 2025 | 66 | $194.7M |
| Q2 2025 | 36 | $39.1M |
| Q1 2025 | 34 | $66.1M |
| Q4 2024 | 33 | $56.0M |
| Q3 2024 | 29 | $63.2M |
| Q2 2024 | 21 | $9.62M |
| Q1 2024 | 18 | $1.90M |
| Q4 2023 | 12 | $209.4K |
| Q3 2023 | 28 | $158.9K |
| Q2 2023 | 26 | $862.7K |
| Q1 2023 | 32 | $16.0M |
| Q4 2022 | 28 | $28.0M |
| Q3 2022 | 27 | $18.4M |
| Q2 2022 | 54 | $34.7M |
| Q1 2022 | 71 | $56.2M |
| Q4 2021 | 75 | $136.0M |
| Q3 2021 | 77 | $175.5M |
| Q2 2021 | 71 | $218.1M |
| Q1 2021 | 70 | $180.4M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Avalo Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 46,648 | $1.01M | 0.28% | +46,648 | New |
| Sio Capital Management, LLC | 10,151 | $220.8K | 0.08% | +10,151 | New |
| Affinity Asset Advisors, LLC | 10,000 | $217.5K | 0.04% | +10,000 | New |
| UBS Group AG | 7,713 | $167.8K | 0.00% | +7,711+385,550.0% | Added |
| ADAR1 Capital Management, LLC | 6,000 | $130.5K | 0.04% | +6,000 | New |
| Natixis | 2,512 | $54.6K | 0.00% | −2,092−45.4% | Reduced |
| BlackRock Inc. | 2,124 | $46.2K | 0.00% | −13,752−86.6% | Reduced |
| Tower Research Capital LLC (TRC) | 1,640 | $35.7K | 0.00% | −126−7.1% | Reduced |
| Royal Bank of Canada | 322 | $7.00K | 0.00% | +184+133.3% | Added |
| Banque Cantonale Vaudoise | 338 | $2.00K | 0.00% | +338 | New |
| Morgan Stanley | 39 | $848 | 0.00% | −5−11.4% | Reduced |
| Wells Fargo & Company | 8 | $175 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 4 | $87 | 0.00% | +4 | New |
| JPMorgan Chase & Co | 2 | $44 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 2 | $44 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 2 | $43 | 0.00% | +1+100.0% | Added |
| Parallel Advisors, LLC | 1 | $22 | 0.00% | +1 | New |
| Old Point Trust & Financial Services N A | 1 | $22 | 0.00% | +1 | New |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −522−100.0% | Sold out |
| First Horizon Advisors, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |